Maze Therapeutics (MAZE) EBITDA (2024 - 2026)
Maze Therapeutics recorded quarterly EBITDA of -$26.6 million in Q1 2026, up 30.23% quarter-over-quarter from -$38.1 million in Q4 2025, and up 24.99% year-over-year from -$21.2 million in Q1 2025.
Maze Therapeutics' EBITDA history runs 3 years deep, the most recent figure standing at -$26.6 million for Q1 2026.
- In Q1 2026, EBITDA rose 24.99% year-over-year to -$26.6 million; the TTM figure through Mar 2026 stood at -$134.1 million (down 3601.85% YoY), while the FY2025 annual figure was -$142.9 million, down 1374.18% from the prior year.
- EBITDA came in at -$26.6 million for Q1 2026 at Maze Therapeutics, up from -$38.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $139.6 million in Q2 2024 to a low of -$76.1 million in Q4 2024.
- A 3-year average of -$17.6 million and a median of -$33.0 million in 2025 frame the typical range for EBITDA.
- On a YoY basis, EBITDA climbed as much as 49.99% in 2025 and fell as far as 126.14% in 2025.
- Maze Therapeutics' EBITDA stood at -$76.1 million in 2024, then jumped by 49.99% to -$38.1 million in 2025, then surged by 30.23% to -$26.6 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$26.6 million, -$38.1 million, and -$33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Maze Therapeutics | 1.37 Bn | 1.37 Bn | 18.21 Mn | -26.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.55 Mn |
| Dec 31, 2025 | -38.06 Mn |
| Sep 30, 2025 | -32.97 Mn |
| Jun 30, 2025 | -36.47 Mn |
| Mar 31, 2025 | -35.40 Mn |
| Dec 31, 2024 | -76.10 Mn |
| Sep 30, 2024 | -24.23 Mn |
| Jun 30, 2024 | 139.56 Mn |
| Mar 31, 2024 | -28.01 Mn |